$377 Million is the total value of Cormorant Asset Management, LP's 54 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QCOR | New | QUESTCOR PHARMACEUTICALS INC | $18,498,000 | – | 200,000 | +100.0% | 4.90% | – |
| CELG | New | CELGENE CORP | $17,176,000 | – | 200,000 | +100.0% | 4.55% | – |
| AKBA | New | AKEBIA THERAPEUTICS INC | $11,116,000 | – | 400,000 | +100.0% | 2.95% | – |
| HRTX | New | HERON THERAPEUTICS INC | $8,624,000 | – | 700,000 | +100.0% | 2.28% | – |
| MNKKQ | New | MALLINCKRODT PUB LTD CO | $7,202,000 | – | 90,000 | +100.0% | 1.91% | – |
| XLRN | New | ACCELERON PHARMA INC | $6,794,000 | – | 200,000 | +100.0% | 1.80% | – |
| VSAR | New | VERSARTIS INC | $5,608,000 | – | 200,000 | +100.0% | 1.49% | – |
| AGTC | New | APPLIED GENETIC TECHNOLOGIES | $5,050,000 | – | 218,600 | +100.0% | 1.34% | – |
| New | PUMA BIOTECHNOLOGY INC | $4,500,000 | – | 5,000 | +100.0% | 1.19% | – | |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $4,451,000 | – | 300,000 | +100.0% | 1.18% | – |
| CBPO | New | CHINA BIOLOGIC PRODS INC | $4,447,000 | – | 100,000 | +100.0% | 1.18% | – |
| QTNT | New | QUOTIENT LTD | $4,180,000 | – | 500,000 | +100.0% | 1.11% | – |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $3,011,000 | – | 150,000 | +100.0% | 0.80% | – |
| CERU | New | CERULEAN PHARMA INC | $2,610,000 | – | 450,000 | +100.0% | 0.69% | – |
| KIN | New | KINDRED BIOSCIENCES INC | $1,864,000 | – | 100,000 | +100.0% | 0.49% | – |
| AGRX | New | AGILE THERAPEUTICS INC | $1,308,000 | – | 150,000 | +100.0% | 0.35% | – |
| CRIS | New | CURIS INC | $1,116,000 | – | 600,000 | +100.0% | 0.30% | – |
| SCYX | New | SCYNEXIS INC | $802,000 | – | 100,000 | +100.0% | 0.21% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.